Literature DB >> 8354301

Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections.

E Pérez-Trallero1, M Urbieta, D Jimenez, J M García-Arenzana, G Cilla.   

Abstract

In a ten-year survey (1983-1992) of quinolone resistance in Escherichia coli causing urinary tract infections in a general practice patient population, 9,934 strains were tested. Resistance increased remarkably from 1989 onwards. The rate of resistance to pipemidic acid was < or = 6% before 1989 and 18% in 1992; the rate of resistance to ciprofloxacin (MIC > or = 4 mg/l) was 0.8% in 1989 and 7.1% in 1992. Although the consumption of older quinolones decreased the total consumption of quinolones increased yearly.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8354301     DOI: 10.1007/bf01964432

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  7 in total

1.  Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.

Authors:  R R Muder; C Brennen; A M Goetz; M M Wagener; J D Rihs
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

2.  Clinical role of the quinolones today and in the future.

Authors:  F A Waldvogel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

3.  Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

Authors:  H M Blumberg; D Rimland; D J Carroll; P Terry; I K Wachsmuth
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

Review 4.  Interaction between antimicrobial consumption and selection of resistant bacterial strains.

Authors:  R C Moellering
Journal:  Scand J Infect Dis Suppl       Date:  1990

5.  A 7-year survey of drug resistance in aerobic and anaerobic fecal bacteria of surgical inpatients: clinical relevance and relation to local antibiotic consumption.

Authors:  P A Kling; R Ostensson; S Granström; L G Burman
Journal:  Scand J Infect Dis       Date:  1989

6.  Development of erythromycin-resistance in Staphylococcus aureus as a consequence of high erythromycin consumption.

Authors:  H Westh; B L Jensen; V T Rosdahl; J Prag
Journal:  J Hosp Infect       Date:  1989-08       Impact factor: 3.926

7.  Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.

Authors:  S P Cohen; L M McMurry; D C Hooper; J S Wolfson; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

  7 in total
  14 in total

1.  Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.

Authors:  S Ozeki; T Deguchi; M Yasuda; M Nakano; T Kawamura; Y Nishino; Y Kawada
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones.

Authors:  J D Goldman; D G White; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study.

Authors:  A Sotto; C M De Boever ; P Fabbro-Peray; A Gouby; D Sirot; J Jourdan
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

4.  Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance.

Authors:  N Lehn; J Stower-Hoffmann; T Kott; C Strassner; H Wagner; M Kronke; W Schneider-Brachert
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

5.  Spontaneous conversion to quinolone and fluoroquinolone resistance among wild-type Escherichia coli isolates in relation to phylogenetic background and virulence genotype.

Authors:  James R Johnson; Brian Johnston; Michael A Kuskowski; Raul Colodner; Raul Raz
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 6.  Risk factors for acquisition of multiply drug-resistant gram-negative bacteria.

Authors:  I M Gould
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

7.  Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine.

Authors:  T A Russo; U B Carlino; A Mong; S T Jodush
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

Review 8.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

9.  Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.

Authors:  P Heisig; R Tschorny
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V.

Authors:  M Kresken; D Hafner; H Mittermayer; L Verbist; E Bergogne-Bérézin; H Giamarellou; S Esposito; B van Klingeren; F H Kayser; D S Reeves
Journal:  Infection       Date:  1994       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.